Zepbound Clinical Trial Findings - Search News

News

Zepbound beats Wegovy for weight loss

Associated Press News on MSN · 2d

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head trial of the blockbuster weight-loss medications.

Becker's Hospital Review · 1d

Zepbound beats Wegovy for weight loss: Study

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England Journal of Medicine and presented at the European Congress on Obesity.

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

1d

Why patients are being forced to switch to a 2nd-choice obesity drug

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Dual-target weight-loss drug is 47% more effective than its rival

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results